Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer’s disease

Table 4 Cost and effectiveness of using Souvenaid under different scenarios

Scenario	Perspective	Treatment indication	Diagnostic test costs	∆ Costs (€)	∆ Effects (QALY)	ICUR (€/QALY)
Baseline	Societal	Only MCI	Included	2633	0.12	22,743
1	Societal	Only MCI	Not included	− 394	0.12	Dominant
2	Societal	MCI and mild AD	Included	7803	0.32	24,392
3	Societal	MCI and mild AD	Not included	4296	0.36	12,076

Societal perspective: includes formal costs, informal costs and caregiver quality of life
QALY quality-adjusted life year, ICUR incremental cost-utility ratio, MCI mild cognitive impairment, AD Alzheimer’s disease

ISSN: 1758-9193